CORRECTION
                                                                                                                                                published: 07 March 2022
                                                                                                                                          doi: 10.3389/fphar.2022.867017




                                           Corrigendum: Impact of
                                           Non-Persistence on Healthcare
                                           Resource Utilization Costs in Patients
                                           With Immune-Mediated Rheumatic
                                           Diseases Initiating Subcutaneous
                                           TNF-Alpha Inhibitors: A
                                           Before-and-After Study
                                           Nuria Carballo 1,2*, Enric Garcia-Alzórriz 3, Olivia Ferrández 1,2,
                                           María Eugenia Navarrete-Rouco 1, Xavier Durán-Jordà 4, Carolina Pérez-García 5,
                                           Jordi Monfort 2,5, Francesc Cots 3 and Santiago Grau 1,2
                                           1
                                             Pharmacy Department, Hospital del Mar – Parc de Salut Mar, Barcelona, Spain, 2Universitat Autònoma de Barcelona,
                                           Barcelona, Spain, 3Management Control Department, Hospital del Mar – Parc de Salut Mar, Barcelona, Spain, 4Methodology and
                                           Biostatistics Support Unit, Institute Hospital del Mar for Medical Research (IMIM), Barcelona, Spain, 5Department of
                                           Rheumatology, Hospital del Mar – Parc de Salut Mar, Barcelona, Spain

                                           Keywords: rheumatic disease, biologics, persistence, healthcare resource utilization and costs, anti TNF
                                           agents



                        Approved by:       A Corrigendum on
              Frontiers Editorial Office,
      Frontiers Media SA, Switzerland
                                           Impact of Non-Persistence on Healthcare Resource Utilization and Costs in Patients With
                  *Correspondence:
                                           Immune-Mediated Rheumatic Diseases Initiating Subcutaneous TNF-Alpha Inhibitors: A
                       Nuria Carballo
                 ncarballo@psmar.cat
                                           Before-and-After Study
                                           by Carballo, N., Garcia-Alzórriz, E., Ferrández, O., Navarrete-Rouco, M. E., Durán-Jordà, X., Pérez-
                    Specialty section:
                                           García, C., Monfort, J., Cots, F., and Grau, S. (2021). Front. Pharmacol. 12:752879. doi: 10.3389/fphar.
         This article was submitted to     2021.752879
         Inflammation Pharmacology,
               a section of the journal    In the published article, there was an error regarding the affiliations for Nuria Carballo, Olivia
            Frontiers in Pharmacology      Ferrández, Jordi Monfort and Santiago Grau. These authors all have an additional affiliation, listed
         Received: 31 January 2022         as “Universitat Autònoma de Barcelona, Barcelona, Spain”.
         Accepted: 31 January 2022             In addition, there was an error in the Acknowledgements section in the original article. The
          Published: 07 March 2022         following statement was should have been included:
                              Citation:        “This study is part of a PhD programme in Medicine of the Universitat Autònoma de Barcelona. This
          Carballo N, Garcia-Alzórriz E,   study was presented, in part, as a poster at the EULAR Virtual Congress, 2–5 June 2021 in Paris, France.”
  Ferrández O, Navarrete-Rouco ME,             The authors apologize for these errors and state that they do not change the scientific conclusions
      Durán-Jordà X, Pérez-García C,
                                           of the article in any way.
Monfort J, Cots F and Grau S (2022)
        Corrigendum: Impact of Non-
                                           Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of
 Persistence on Healthcare Resource        their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this
     Utilization Costs in Patients With    article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
         Immune-Mediated Rheumatic
Diseases Initiating Subcutaneous TNF-      Copyright © 2022 Carballo, Garcia-Alzórriz, Ferrández, Navarrete-Rouco, Durán-Jordà, Pérez-García, Monfort, Cots and Grau.
       Alpha Inhibitors: A Before-and-     This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use,
                           After Study.    distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited
        Front. Pharmacol. 13:867017.       and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or
     doi: 10.3389/fphar.2022.867017        reproduction is permitted which does not comply with these terms.




Frontiers in Pharmacology | www.frontiersin.org                                     1                                            March 2022 | Volume 13 | Article 867017